Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ezekowitz

Showing results (691-700 of 842) with videos related to

Pageof 85
Sort By:
Journal of Thrombosis and Thrombolysis|February 7, 2012
Baseline NT-proBNP and biomarkers of inflammation and necrosis in patients with ST-segment elevation myocardial infarction: insights from the APEX-AMI trialSean van Diepen, Matthew T Roe, Renato D Lopes, et al.
Heart (British Cardiac Society)|June 28, 2020
Patterns of oral anticoagulation use with cardioversion in clinical practiceKyle Geurink, DaJuanicia Holmes, Michael D Ezekowitz, et al.
Progress in Cardiovascular Diseases|May 1, 2022
Assessing race and ethnicity differences in outcomes based on GDMT and target NT-proBNP in patients with heart failure with reduced ejection fraction: An analysis of the GUIDE-IT studyMohit Pahuja, Eric S Leifer, John-Ross D Clarke, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|December 28, 2020
Heterogeneity of diabetes as a risk factor for major adverse cardiovascular events in anticoagulated patients with atrial fibrillation: an analysis of the ARISTOTLE trialRaffaele De Caterina, Giuseppe Patti, Johan Westerbergh, et al.
JACC. Heart Failure|May 8, 2025
Sex Differences in Diabetic Cardiomyopathy and Treatment Response to AT-001: Insights From the ARISE-HF StudyVanessa Blumer, James L Januzzi, Yuxi Liu, et al.
Thrombosis and Haemostasis|November 4, 2011
Comprehensive risk reduction in patients with atrial fibrillation: Emerging diagnostic and therapeutic options. Executive summary of the report from the 3rd AFNET/EHRA consensus conferencePaulus Kirchhof, Gregory Y H Lip, Isabelle C Van Gelder, et al.
American Heart Journal|April 29, 2014
Rationale and design of the eXplore the efficacy and safety of once-daily oral riVaroxaban for the prEvention of caRdiovascular events in patients with nonvalvular aTrial fibrillation scheduled for cardioversion trial: A comparison of oral rivaroxaban once daily with dose-adjusted vitamin K antagonists in patients with nonvalvular atrial fibrillation undergoing elective cardioversionMichael D Ezekowitz, Riccardo Cappato, Allan L Klein, et al.
European Journal of Heart Failure|June 19, 2024
Characterization of serum phosphate levels over time with intravenous ferric carboxymaltose versus placebo as treatment for heart failure with reduced ejection fraction and iron deficiency: An exploratory prospective substudy from HEART-FIDNina Nouhravesh, Jyotsna Garg, Frank W Rockhold, et al.
Journal of Cardiac Failure|July 9, 2010
HFSA 2010 Comprehensive Heart Failure Practice Guideline, JoAnn Lindenfeld, Nancy M Albert, et al.
The American Journal of Cardiology|September 3, 2018
Relation of Volume Overload to Clinical Outcomes in Acute Heart Failure (From ASCEND-HF)Marat Fudim, Kishan S Parikh, Allison Dunning, et al.
Pageof 85

Showing results (691-700 of 842) with videos related to

Sort By:
Pageof 85
Journal of Thrombosis and Thrombolysis|February 7, 2012
Baseline NT-proBNP and biomarkers of inflammation and necrosis in patients with ST-segment elevation myocardial infarction: insights from the APEX-AMI trialSean van Diepen, Matthew T Roe, Renato D Lopes, et al.
Heart (British Cardiac Society)|June 28, 2020
Patterns of oral anticoagulation use with cardioversion in clinical practiceKyle Geurink, DaJuanicia Holmes, Michael D Ezekowitz, et al.
Progress in Cardiovascular Diseases|May 1, 2022
Assessing race and ethnicity differences in outcomes based on GDMT and target NT-proBNP in patients with heart failure with reduced ejection fraction: An analysis of the GUIDE-IT studyMohit Pahuja, Eric S Leifer, John-Ross D Clarke, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|December 28, 2020
Heterogeneity of diabetes as a risk factor for major adverse cardiovascular events in anticoagulated patients with atrial fibrillation: an analysis of the ARISTOTLE trialRaffaele De Caterina, Giuseppe Patti, Johan Westerbergh, et al.
JACC. Heart Failure|May 8, 2025
Sex Differences in Diabetic Cardiomyopathy and Treatment Response to AT-001: Insights From the ARISE-HF StudyVanessa Blumer, James L Januzzi, Yuxi Liu, et al.
Thrombosis and Haemostasis|November 4, 2011
Comprehensive risk reduction in patients with atrial fibrillation: Emerging diagnostic and therapeutic options. Executive summary of the report from the 3rd AFNET/EHRA consensus conferencePaulus Kirchhof, Gregory Y H Lip, Isabelle C Van Gelder, et al.
American Heart Journal|April 29, 2014
Rationale and design of the eXplore the efficacy and safety of once-daily oral riVaroxaban for the prEvention of caRdiovascular events in patients with nonvalvular aTrial fibrillation scheduled for cardioversion trial: A comparison of oral rivaroxaban once daily with dose-adjusted vitamin K antagonists in patients with nonvalvular atrial fibrillation undergoing elective cardioversionMichael D Ezekowitz, Riccardo Cappato, Allan L Klein, et al.
European Journal of Heart Failure|June 19, 2024
Characterization of serum phosphate levels over time with intravenous ferric carboxymaltose versus placebo as treatment for heart failure with reduced ejection fraction and iron deficiency: An exploratory prospective substudy from HEART-FIDNina Nouhravesh, Jyotsna Garg, Frank W Rockhold, et al.
Journal of Cardiac Failure|July 9, 2010
HFSA 2010 Comprehensive Heart Failure Practice Guideline, JoAnn Lindenfeld, Nancy M Albert, et al.
The American Journal of Cardiology|September 3, 2018
Relation of Volume Overload to Clinical Outcomes in Acute Heart Failure (From ASCEND-HF)Marat Fudim, Kishan S Parikh, Allison Dunning, et al.
Pageof 85